Clinical Trial Update: [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the radiopharmaceutical [212Pb]VMT-Alpha-NET across multiple somatostatin receptor–positive cancers, with recruitment ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Neuroendocrine Tumor
• Head and Neck Cancer
• Kidney Cancer
• Paraganglioma
• Pheochromocytoma
• Small Cell Lung Cancer

Drugs mentioned

• [212Pb]VMT-alpha-NET (212Pb-VMT-alpha-NET)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Head and Neck Tumors, Kidney Cancers | Phase 1 | Status: RECRUITING